Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 2, pp 384–393 | Cite as

Use of medications for secondary prevention in stroke patients at hospital discharge in Australia

  • Ashraf EissaEmail author
  • Ines Krass
  • Beata V. Bajorek
Research Article

Abstract

Background Stroke is one of the leading causes of death and disability. Significant proportions (33 %) of stroke presentations are by patients with a previous stroke or transient ischaemic attack. Consequently, the stroke management guidelines recommend that all ischaemic stroke patients should receive three key evidence-based preventive drug therapies: antihypertensive drug therapy, a statin and an antithrombotic drug therapy (anticoagulant and/or antiplatelet). Objective To determine the rates of utilization of the three key evidence-based drug therapies for the secondary prevention of stroke and to identify factors associated with use of treatment at discharge. Setting Five metropolitan hospitals in New South Wales, comprising two tertiary referral centres and three district hospitals. Method A retrospective clinical audit was conducted in the study hospitals. Patients discharged with a principal diagnosis of ischaemic stroke during a 12-month time period (July 2009–2010) were identified for review. Main outcome measure The rate of utilization of each of the three key evidence-based drug therapies and the factors associated with use of treatment at discharge. Results A total of 521 medical records were reviewed. Of these, 469 patients were discharged alive with a mean age of 73.6 ± 14.4 years. Overall, 75.4 % were prescribed an antihypertensive agent at discharge versus only 65.7 % on admission (P < 0.05). Three hundred-sixty patients (77.6 % of the eligible patients) were prescribed a statin at discharge (compared to only 43.9 % on admission, P < 0.05), of whom 74.0 % received monotherapy. Almost all (97.6 %) eligible patients were prescribed an antithrombotic drug therapy at discharge, of whom 68.5 % were prescribed monotherapy and 28.2 % were prescribed dual therapy. Only 60.0 % of eligible patients were discharged on all three key guideline recommended secondary preventive drug therapies. Multivariate logistic regression analyses showed that hypertension (OR 6.67; 95 % CI 4.35–11.11), hypercholesterolemia (OR 2.04; 95 % CI 1.32–3.23), and discharge destination (OR 0.22; 95 % CI 0.10–0.48) were associated with the utilization of all three guideline recommended therapies. Conclusion There is a scope for improvement in implementing the stroke management guidelines when it comes to prescribing secondary preventive drug therapies using antihypertensives, antithrombotics and statins. Appropriate risk/benefit assessment is indispensable for optimal prescribing and maximizing patient outcomes, particularly in older people.

Keywords

Australia Cerebrovascular accident Clinical audit Medical care Secondary prevention Stroke 

Notes

Acknowledgments

The authors would like to thank Professor Christopher Levi, Associate professor Jonathan Sturm, and Rabsima Ibrahim for supporting this research project. The authors would also like to thank the casemix, statistics, and medical records departments at each hospital for providing support for this study.

Funding

No external funding has been obtained for the study.

Conflicts of interest

The authors declare no conflicts of interest.

References

  1. 1.
    Donnan G, Fisher M, Macleod M, Davis S. Stroke. The Lancet. 2008;371:1612–23.CrossRefGoogle Scholar
  2. 2.
    Islam MS, Anderson CS, Hankey GJ. Trends in incidence and outcome of stroke in Perth, Western Australia during 1989–2001. Stroke. 2008;139:776–82.CrossRefGoogle Scholar
  3. 3.
    Rothwell PM, Coull AJ, Giles MF. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004. Lancet. 2004;363:1925–33.PubMedCrossRefGoogle Scholar
  4. 4.
    National stroke foundation (Internet). National Stroke Audit - Acute Services Clinical Audit Report 2011, Melbourne, Australia; 2011. [cited 2013 October 9) ISBN 978-0-9805933-7-2 Available from: http://strokefoundation.com.au/site/media/National_stroke_audit_acute_services_clinical_audit_report_2011.pdf.
  5. 5.
    Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth community stroke study. Stroke. 2004;35:731–5.PubMedCrossRefGoogle Scholar
  6. 6.
    National stroke foundation (Internet). Clinical Guidelines for Stroke Management 2010. Melbourne Australia; 2010. [cited 2013 October 9) ISSBN0-978-0-9805933-3-4 Available from:http://strokefoundation.com.au/site/media/Clinical_Guidelines_Acute_Management_Recommendations_2010.pdf.
  7. 7.
    Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119:300S–20S.PubMedCrossRefGoogle Scholar
  8. 8.
    Kokotailo R, Hill M. Coding of stroke and stroke risk factors using international classification of diseases. Stroke. 2005;36:1776–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Corella D, Qi L, Tai ES, Deurenberg-Yap M, Tan CE, Chew SK, et al. Perilipin gene variation determines higher susceptibility to insulin resistance in Asian women when consuming a high-saturated fat, low-carbohydrate diet. Diabetes Care. 2006;29:1313–9.PubMedCrossRefGoogle Scholar
  10. 10.
    van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American heart association/American stroke association stroke council. Stroke. 2007;38:1655–711.PubMedCrossRefGoogle Scholar
  12. 12.
    Ovbiagele B, Hills NK, Saver JL, Johnston SC. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA. Neurology. 2006;66:313–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Bajorek B, Krass I, Ogle S, Duguid M, Shenfield G. The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation. Australas J Ageing. 2002;21:36–41.CrossRefGoogle Scholar
  14. 14.
    Munoz M, Marrugat J. Secondary prevention of coronary heart disease is less aggressive in patients over 64 years. Rev Esp Cardiol. 2003;56:586–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Philippe F, Danchin N, Quentzel S. Utilization of the principal therapeutic classes for cardiovascular prevention in elderly patients seen by cardiologists. Ann Cardiol Angeiol. 2004;53:339–46.CrossRefGoogle Scholar
  16. 16.
    Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol. 2003;55:604–8.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Strandberg T, Pitkala K, Kulp S. Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population based cross-sectional survey in helsinki, finland. Eur J Clin Pharmacol. 2001;57:513–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Lawlor D, Whincup P, Emberson JR. The challenge of secondary prevention for coronary heart disease in older patients: findings from the British women’s heart and health study and the British regional heart study. Fam Pract. 2004;21:582–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Castelino RL, Chen TF, Guddattu V, Bajorek BV. Use of evidence-based therapy for the prevention of cardiovascular events among older people. Eval Health Prof. 2010;33:276–301.PubMedCrossRefGoogle Scholar
  20. 20.
    Bajorek BV, Ren S. Utilisation of antithrombotic therapy for stroke prevention in atrial fibrillation in a Sydney hospital: then and now. Int J Clin Pharm. 2012;34:88–97.PubMedCrossRefGoogle Scholar
  21. 21.
    Sanossian N, Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol. 2009;8:1031–41.PubMedCrossRefGoogle Scholar
  22. 22.
    EAFT (European Atrial Fibrillation Trial). Study group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255–62.Google Scholar
  23. 23.
    Rigler SK, Webb MJ, Patel AT, Lai SM, Duncan PW. Use of antihypertensive and antithrombotic medications after stroke in community-based care. Ann Pharmacother. 2001;35:811–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Lichtman JH, Naert L, Allen NB, Watanabe E, Jones SB, Barry LC, et al. Use of antithrombotic medications among elderly ischemic stroke patients. Circ Cardiovasc Qual Outcomes. 2011;4:30–8.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Glader EL, Stegmayr B, Norrving B, Terént A, Hulter-Asberg K, Wester PO, et al. Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective. J Intern Med. 2004;255:22–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American heart association/American stroke association council on stroke. Stroke. 2006;37:577–617.PubMedCrossRefGoogle Scholar
  27. 27.
    Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  29. 29.
    Diener HC, Bogousslavsky J, Brass LM. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331.PubMedCrossRefGoogle Scholar
  30. 30.
    Bhatt DL, Fox KA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706.PubMedCrossRefGoogle Scholar
  31. 31.
    Usman MH, Notaro LA, Nagarakanti R. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol. 2009;103:1107.PubMedCrossRefGoogle Scholar
  32. 32.
    National stroke foundation (Internet). National Stroke Audit Acute Services Organisational Survey Report 2009. Melbourne Australia; 2009. (cited 2013 October 9) ISBN0-9752292-4-6 Available from: http://strokefoundation.com.au/site/media/National_stroke_audit_acute_services_organisational_survey_report_2009.pdf.
  33. 33.
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–41.CrossRefGoogle Scholar
  34. 34.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ. 2008;17:114–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163:669–76.PubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  1. 1.Faculty of Pharmacy (A15)University of SydneySydneyAustralia
  2. 2.Royal North Shore HospitalSydneyAustralia
  3. 3.University of Technology SydneySydneyAustralia

Personalised recommendations